Acromegaly treatment drug Lanrui peptide acetate slow release injection (pre filled) was officially approved!

Ipsen China, the world's leading biopharmaceutical company, announced today that China's National Drug Administration has approved the treatment of acromegaly in which lanruitide acetate slow-release injection (precharge) is still abnormal in blood growth hormone and insulin-like growth factor-1 levels after surgery and / or radiotherapy, or cannot be operated and / or radiotherapy Lanruitide acetate sustained-release injection (precharge) is the first ready-to-use sustained-release preparation based on self-assembled nanotube technology, which has been registered and listed in about 70 countries around the world, and widely used in the clinical treatment of acromegaly Its listing will accelerate the in-depth development of Epson in China in the field of rare diseases, and bring more patients with innovative treatment methods Chen Jialin, general manager of Yipu Health China, said: "Yipu health is committed to providing advanced treatment programs for Chinese patients in the field of rare diseases We have a deep understanding of the unmet needs of acromegaly patients in treatment, hoping to bring more new treatment options for clinicians and patients, and help more patients improve their quality of life At the same time, we would like to thank the government for promoting the rare disease policy In the next 3-5 years, we will try our best to introduce more innovative products for the treatment of rare and even extremely rare diseases into China faster Under the guidance of the patient-centered principle, we will spare no effort to work with all parties to meet the challenges of rare diseases in China, so that patients with diseases will not wait in hopelessness " The newly approved slow-release lanruitide acetate injection (precharge) is a technical innovation, belonging to the first ready-to-use slow-release preparation based on self-assembled nanotube technology At present, the product has three specifications of 60mg, 90mg and 120mg The data showed that the patients with good biochemical control could extend the injection interval by 120mg every 6 weeks or 8 weeks Professor Wang Haijun, director of Neurosurgery Department of the First Affiliated Hospital of Sun Yat sen University and director of pituitary tumor diagnosis and treatment center, said: "acromegaly, as a rare and insidious disease that seriously threatens people's health, needs long-term treatment and follow-up by clinicians and patients Research shows that the mortality rate of acromegaly patients is 1.3-1.9 times that of the same age group At present, surgical treatment is the first choice, and the overall cure rate is about 65% If the postoperative biochemistry is not relieved, the patient needs to receive comprehensive treatment including medicine and radiation In terms of drug selection, we can choose a variety of drugs including LRP, and adjust the treatment plan according to the individual situation At the same time, we also call on all sectors of society to pay more attention to acromegaly, promote the early diagnosis rate of the disease, strengthen the awareness of long-term follow-up, promote the popularization of standard diagnosis and treatment programs, and help improve the quality of life of acromegaly patients, so that patients can recover as soon as possible " Adorable adorable